The Brilife vaccine, developed by the Israel Institute for Biological Research, appears to give long-term defense against the coronavirus. The 230 trial volunteers who received the highest dosage of the vaccine were still fully protected six months after vaccination.
A pre-clinical trial of opaganib from Israel’s Redhill (see previously) shows that its strong antiviral and anti-inflammatory activities can inhibit any variant of the SARS-Cov-2 virus. Opaganib targets SK2 - a key enzyme used by the virus to replicate, irrespective of spike protein mutations.
Israel’s Antidote Health is bringing a virtual Kupat Holim (health fund) to the US for the benefit of uninsured and under-insured Americans. Using a digital service and AI, Antidote Health says it can cut the costs of the service to about a tenth of what Americans pay now.
United Hatzalah EMT Gal was just in time when he used his own son’s EpiPen to save the life of a 5-year-old boy who suffered an anaphylactic reaction in Netanya. It was the birthday of the boy’s mother and she said that the life of her son was the best birthday present she had ever received.
In 2018, 24-year-old Netanel was shot in the head by a terrorist. Minimally conscious for several months, he is now making slow but steady recovery progress, against all odds, at Sheba Medical Center’s Brain Injury Rehabilitation Unit.
Israel’s illumigyn (see previously) has signed a Memorandum of Understanding with Dubai-based company DHI 2048 to deploy 2,500 units of its Gynescope cloud platform service. It will boost the availability of imaging and examination to improve women’s healthcare in the region.
Israel’s Yemoja (see previously) and Israel’s MIGAL Galilee Research Institute are leading a 4-year research initiative to find algae-sourced compounds to help Inflammatory Bowel Disease (IBD) sufferers. The 21-member Algae4IBD consortium has received a €7.5 million EU Horizon 2020 award.
Israel’s Ibex Medical (see previously) has launched its new Galen Gastric system, to detect gastrointestinal cancer, at Israel’s Maccabi HMO (Health Management organization). Maccabi is the world’s only health system to use AI for multi-tissue detection (breast, prostate and gastric).
In a study of over 9,000 patients Tel Aviv University researchers used previously ignored “silent mutations” analysis techniques to increase chances of detecting cancer early. They proved that the huge volume of genomic and gene expression data available can help extend survival times and save lives.
Scientists at the Hebrew University of Jerusalem successfully trialed TriCor (fenofibrate see previously) on 15 severely ill Covid patients. 14 were weaned off their ventilators within a week. TriCor targets inflammation-producing lipids produced by the coronavirus.